Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Undisclosed Program 2
- Development stage
- Preclinical
- Lead developer
- 280Bio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Undisclosed Program 2 is an early-stage, orally bioavailable small molecule inhibitor being developed by 280Bio. It is designed to target RAS mutant proteins for the treatment of solid tumors harboring RAS mutations. Currently in the discovery phase, this program is part of 280Bio's broader pipeline focused on the RAS/MAPK pathway, which includes pan-RAS and KRAS-specific inhibitors. As an undisclosed program, specific details regarding its chemical structure or the exact RAS variants it targets have not been publicly released.
02
Targets
HRAS (H-Ras protein)
Beyond the preview
Go deeper on Undisclosed Program 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Undisclosed Program 2.